{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T19:18:24Z","timestamp":1788722304278,"version":"build-2803163510"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"18","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>To summarize current literature evaluating tranexamic acid in the management of intracranial bleeding associated with traumatic and nontraumatic brain injuries and implications for clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Intracranial hemorrhage, regardless of etiology, is associated with high morbidity and mortality. Tranexamic acid is an antifibrinolytic with anti-inflammatory properties shown to reduce mortality in trauma patients with extracranial injuries. In traumatic brain injury, a large randomized trial found no difference in outcomes when tranexamic acid was compared to placebo; however, subgroup analyses suggested that it may reduce head injury\u2013related mortality in the context of mild-to-moderate injury if treatment occurs within 1 hour of symptom onset. More recent out-of-hospital data have disputed these findings and even suggested harm in severely injured patients. In spontaneous, nontraumatic intracranial hemorrhage, treatment with tranexamic acid did not result in a difference in functional status; however, rates of hematoma expansion, even though modest, were significantly reduced. In aneurysmal subarachnoid hemorrhage, tranexamic acid may prevent rebleeding, but has not led to improved outcomes or reduced mortality, and there is concern for increased incidence of delayed cerebral ischemia. Overall, tranexamic acid has not been shown to result in increased risk of thromboembolic complications across these classes of brain injury.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Despite its favorable safety profile overall, tranexamic acid does not seem to improve functional outcomes and cannot be routinely recommended. More data are needed to determine which head injury subpopulations are most likely to benefit from tranexamic acid and which patients are at increased risk for harm.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxad134","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T08:12:59Z","timestamp":1686211979000},"page":"1213-1222","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic review: The role of tranexamic acid in management of traumatic brain injury, nontraumatic intracranial hemorrhage, and aneurysmal subarachnoid hemorrhage"],"prefix":"10.1093","volume":"80","author":[{"given":"Jana","family":"Sigmon","sequence":"first","affiliation":[{"name":"Harris Health System , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli L","family":"Crowley","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UPMC Children\u2019s Hospital of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M","family":"Groth","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center , Rochester, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"issue":"9","key":"2023090706235331200_CIT0001","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1164\/rccm.201103-0475CI","article-title":"Intracranial hemorrhage","volume":"184","author":"Naidech","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2023090706235331200_CIT0002","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.emc.2012.06.003","article-title":"Intracranial hemorrhage","volume":"30","author":"Caceres","year":"2012","journal-title":"Emerg Med Clin North Am"},{"issue":"1","key":"2023090706235331200_CIT0003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00068-017-0833-3","article-title":"Fibrinolysis in trauma: a review","volume":"44","author":"Madurska","year":"2018","journal-title":"Eur J Trauma Emerg Surg"},{"issue":"4","key":"2023090706235331200_CIT0004","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jamcollsurg.2016.01.006","article-title":"Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2,540 severely injured patients","volume":"222","author":"Moore","year":"2016","journal-title":"J Am Coll Surg"},{"issue":"6","key":"2023090706235331200_CIT0005","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s12630-021-01967-7","article-title":"Tranexamic acid: current use in obstetrics, major orthopedic, and trauma surgery","volume":"68","author":"Wong","year":"2021","journal-title":"Can J Anaesth"},{"issue":"3","key":"2023090706235331200_CIT0006","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.emc.2019.04.001","article-title":"Intracranial hemorrhage and intracranial hypertension","volume":"37","author":"Marcolini","year":"2019","journal-title":"Emerg Med Clin North Am"},{"key":"2023090706235331200_CIT0007","author":"Tranexamic acid injection","year":"2021"},{"issue":"4","key":"2023090706235331200_CIT0008","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5603\/AIT.a2015.0011","article-title":"Tranexamic acid: a clinical review","volume":"47","author":"Ng","year":"2015","journal-title":"Anaesthesiol Intensive Ther"},{"issue":"3","key":"2023090706235331200_CIT0009","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/TA.0000000000001792","article-title":"Increased risk of fibrinolysis shutdown among severely injured trauma patients receiving tranexamic acid","volume":"84","author":"Meizoso","year":"2018","journal-title":"J Trauma Acute Care Surg"},{"key":"2023090706235331200_CIT0010","author":"Centers for Disease Control and Prevention"},{"issue":"2","key":"2023090706235331200_CIT0011","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.mcna.2019.11.001","article-title":"Traumatic brain injury: an overview of epidemiology, pathophysiology, and management","volume":"104","author":"Capizzi","year":"2020","journal-title":"Med Clin North Am"},{"key":"2023090706235331200_CIT0012","doi-asserted-by":"crossref","first-page":"d3795","DOI":"10.1136\/bmj.d3795","article-title":"Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo-controlled trial (CRASH-2 Intracranial Bleeding Study)","volume":"343","author":"CRASH-2 Collaborators, Intracranial Bleeding Study","year":"2011","journal-title":"BMJ"},{"issue":"9","key":"2023090706235331200_CIT0013","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1161\/01.STR.0000089030.04120.0E","article-title":"Antifibrinolytic therapy for aneurysmal subarachnoid hemorrhage: a major update of a Cochrane review","volume":"34","author":"Roos","year":"2003","journal-title":"Stroke"},{"issue":"9734","key":"2023090706235331200_CIT0014","first-page":"23","article-title":"CRASH-2 Trial Collaborators. Effects of tranexamic acid on death","volume":"376","author":"Shakur","year":"2010","journal-title":"vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet"},{"key":"2023090706235331200_CIT0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-227X-13-20","article-title":"Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial","volume":"13","author":"Yutthakasemsunt","year":"2013","journal-title":"BMC Emerg Med"},{"issue":"10210","key":"2023090706235331200_CIT0016","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(19)32233-0","article-title":"Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial","volume":"394","author":"CRASH-3 Trial Collaborators","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"2023090706235331200_CIT0017","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jama.2020.8958","article-title":"Effect of out-of-hospital tranexamic acid vs placebo on 6-month functional neurologic outcomes in patients with moderate or severe traumatic brain injury","volume":"324","author":"Rowell","year":"2020","journal-title":"JAMA"},{"key":"2023090706235331200_CIT0018","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40560-020-00460-5","article-title":"Efficacy and safety of tranexamic acid administration in traumatic brain injury patients: a systematic review and meta-analysis","volume":"8","author":"Yokobori","year":"2020","journal-title":"J Intensive Care"},{"issue":"3","key":"2023090706235331200_CIT0019","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/jamaneurol.2020.4596","article-title":"Association between prehospital tranexamic acid administration and outcomes of severe traumatic brain injury","volume":"78","author":"Bossers","year":"2021","journal-title":"JAMA Neurol"},{"issue":"8","key":"2023090706235331200_CIT0020","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics\u20142021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"2023090706235331200_CIT0021","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(09)70340-0","article-title":"Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis","volume":"9","author":"Van Asch","year":"2010","journal-title":"Lancet Neurol"},{"issue":"1","key":"2023090706235331200_CIT0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.STR.28.1.1","article-title":"Early hemorrhage growth in patients with intracerebral hemorrhage","volume":"28","author":"Brott","year":"1997","journal-title":"Stroke"},{"issue":"2","key":"2023090706235331200_CIT0023","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/STROKEAHA.109.552919","article-title":"Options to restrict hematoma expansion after spontaneous intracerebral hemorrhage","volume":"41","author":"Steiner","year":"2010","journal-title":"Stroke"},{"issue":"6","key":"2023090706235331200_CIT0024","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/01.WNL.0000138428.40673.83","article-title":"hematoma expansion, and outcome of intracerebral hemorrhage","volume":"63","author":"Flibotte","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"2023090706235331200_CIT0025","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/imj.12034","article-title":"Warfarin-related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates","volume":"43","author":"Hanger","year":"2013","journal-title":"Intern Med J"},{"issue":"10135","key":"2023090706235331200_CIT0026","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(18)31033-X","article-title":"TICH-2 Investigators. Tranexamic acid for hyperacute primary IntraCerebral Hemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial","volume":"391","author":"Sprigg","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"2023090706235331200_CIT0027","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S1474-4422(20)30369-0","article-title":"Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial","volume":"19","author":"Meretoja","year":"2020","journal-title":"Lancet Neurol"},{"issue":"10269","key":"2023090706235331200_CIT0028","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(20)32518-6","article-title":"ULTRA Investigators. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial","volume":"397","author":"Post","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2023090706235331200_CIT0029","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/STROKEAHA.109.565382","article-title":"The spot sign score in primary intracerebral hemorrhage identifies patients at highest risk of in-hospital mortality and poor outcome among survivors","volume":"41","author":"Almandoz","year":"2010","journal-title":"Stroke"},{"issue":"12","key":"2023090706235331200_CIT0030","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1161\/STROKEAHA.112.664003","article-title":"Clinical applications of the computed tomography angiography spot sign in acute intracerebral hemorrhage: a review","volume":"43","author":"Brouwers","year":"2012","journal-title":"Stroke"},{"key":"2023090706235331200_CIT0031","doi-asserted-by":"crossref","first-page":"258161","DOI":"10.1155\/2015\/258161","article-title":"The motor recovery related with brain lesion in patients with intracranial hemorrhage","volume":"2015","author":"Lee","year":"2015","journal-title":"Behav Neurol"},{"issue":"8","key":"2023090706235331200_CIT0032","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1161\/STROKEAHA.120.032426","article-title":"Tranexamic acid for prevention of hematoma expansion in intracerebral hemorrhage patients with or without spot sign","volume":"52","author":"Ovesen","year":"2021","journal-title":"Stroke"},{"key":"2023090706235331200_CIT0033","author":"Neuroscience Trials Australia"},{"issue":"2","key":"2023090706235331200_CIT0034","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/STROKEAHA.117.019328","article-title":"Predictors of in-hospital death after aneurysmal subarachnoid hemorrhage: analysis of a nationwide database (Swiss SOS [Swiss Study on Aneurysmal Subarachnoid Hemorrhage])","volume":"49","author":"Steinen","year":"2018","journal-title":"Stroke"},{"issue":"5","key":"2023090706235331200_CIT0035","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/00006123-200211000-00001","article-title":"The probability of sudden death from rupture on intracranial aneurysms: a meta-analysis","volume":"51","author":"Huang","year":"2002","journal-title":"Neurosurgery"},{"issue":"2","key":"2023090706235331200_CIT0036","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1227\/NEU.0000000000001042","article-title":"Predictors of poor quality of life 1 year after subarachnoid hemorrhage","volume":"78","author":"Taufique","year":"2016","journal-title":"Neurosurgery"},{"issue":"4","key":"2023090706235331200_CIT0037","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1161\/01.STR.5.4.557","article-title":"Cooperative study of intracranial aneurysms and subarachnoid hemorrhage. Report on a randomized treatment study. 3. Intracranial surgery","volume":"5","author":"Graf","year":"1974","journal-title":"Stroke"},{"issue":"2","key":"2023090706235331200_CIT0038","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/01.STR.13.2.256","article-title":"Current status of antifibrinolytic therapy for treatment of patients with aneurysmal subarachnoid hemorrhage","volume":"13","author":"Adams","year":"1982","journal-title":"Stroke"},{"issue":"6118","key":"2023090706235331200_CIT0039","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/bmj.1.6118.945","article-title":"Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms","volume":"1","author":"Maurice-Williams","year":"1978","journal-title":"Br Med J"},{"issue":"8","key":"2023090706235331200_CIT0040","first-page":"D001245","article-title":"Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage","volume":"2013","author":"Baharoglu","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2023090706235331200_CIT0041","doi-asserted-by":"crossref","first-page":"15275","DOI":"10.1038\/s41598-021-94727-y","article-title":"Tranexamic acid in non-traumatic intracranial bleeding: a systematic review and meta-analysis","volume":"11","author":"Bouillon-Minois","year":"2021","journal-title":"Sci Rep"},{"key":"2023090706235331200_CIT0042","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ajem.2021.09.047","article-title":"Tranexamic acid for subarachnoid hemorrhage: a systematic review and meta-analysis","volume":"50","author":"Feng","year":"2021","journal-title":"Am J Emerg Med"},{"key":"2023090706235331200_CIT0043","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ajem.2021.09.051","article-title":"Efficacy and safety of tranexamic acid in aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials","volume":"50","author":"Liu","year":"2021","journal-title":"Am J Emerg Med"},{"key":"2023090706235331200_CIT0044","doi-asserted-by":"crossref","first-page":"710495","DOI":"10.3389\/fneur.2021.710495","article-title":"Safety and efficacy of tranexamic acid in aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials","volume":"12","author":"Ren","year":"2022","journal-title":"Front Neurol"},{"issue":"4","key":"2023090706235331200_CIT0045","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3171\/jns.2002.97.4.0771","article-title":"Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study","volume":"97","author":"Hillman","year":"2002","journal-title":"J Neurosurg"},{"key":"2023090706235331200_CIT0046","article-title":"Tranexamic acid","volume-title":"IBM Micromedex With Watson [proprietary data]","year":"2019"},{"issue":"3","key":"2023090706235331200_CIT0047","doi-asserted-by":"crossref","first-page":"36","DOI":"10.55460\/ZWV3-5CBW","article-title":"The use of tranexamic acid in tactical combat casualty care: TCCC Proposed Change 20-02","volume":"20","author":"Drew","year":"2020","journal-title":"J Spec Oper Med"},{"issue":"1","key":"2023090706235331200_CIT0048","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s13054-021-03799-9","article-title":"Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis","volume":"25","author":"Murao","year":"2021","journal-title":"Crit Care"},{"issue":"9","key":"2023090706235331200_CIT0049","doi-asserted-by":"crossref","first-page":"e002716","DOI":"10.1136\/bmjgh-2020-002716","article-title":"Cost-effectiveness analysis of tranexamic acid for the treatment of traumatic brain injury, based on the results of the CRASH-3 randomised trial: a decision modelling approach","volume":"5","author":"Williams","year":"2020","journal-title":"BMJ Global Health"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxad134\/50682898\/zxad134.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/18\/1213\/51406012\/zxad134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/18\/1213\/51406012\/zxad134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T06:25:26Z","timestamp":1694067926000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/18\/1213\/7191237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":49,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,6,6]]},"published-print":{"date-parts":[[2023,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxad134","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,15]]},"published":{"date-parts":[[2023,6,6]]}}}